Paion AG (PAIOF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Paion AG (PAIOF) trades at $0.01 with AI Score 69/100 (Grade B+). Paion AG is a specialty pharmaceutical company focused on developing and commercializing hospital-based drugs for sedation, anesthesia, and critical care. Market cap: $75,264, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for PAIOF: PAIOF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PAIOF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PAIOF: 4/4 perspectives are bullish. Dominant signal: Seth Klarman bullish.
Paion AG (PAIOF) Healthcare & Pipeline Overview
Paion AG is a German specialty pharmaceutical company focused on hospital-based sedation, anesthesia, and critical care drugs. Their lead product, Remimazolam, targets procedural sedation, general anesthesia, and ICU sedation markets. Paion operates in a competitive pharmaceutical landscape, partnering to expand its global reach.
What Is the Investment Thesis for PAIOF?
Paion AG presents a focused investment opportunity within the specialty pharmaceutical sector, driven primarily by the potential of Remimazolam. The drug's ongoing clinical development for various sedation and anesthesia applications represents a significant catalyst for growth. Successful clinical trials and subsequent regulatory approvals could substantially increase Paion's market value. However, the company's negative P/E ratio of -4.44 and negative profit margin of -1.7% indicate financial challenges. Investors should closely monitor clinical trial outcomes, regulatory decisions, and the company's ability to achieve profitability. A high beta of 4.0 suggests significant volatility relative to the market.
Based on FMP financials and quantitative analysis
PAIOF Key Highlights
- Gross Margin of 94.1% indicates strong pricing power on existing products.
- Negative P/E ratio of -4.44 reflects current losses and the company's growth stage.
- Market Cap of $0.00B indicates that the company is a micro-cap stock.
- Beta of 4.00 suggests high volatility compared to the overall market.
- Partnerships with Cosmo Pharmaceuticals, Wuhan Humanwell, Hana Pharm, Yichang Humanwell, and Mundipharma expand market reach.
Who Are PAIOF's Competitors?
PAIOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $4.44 | +5.21% | $1.39B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| NBIX Neurocrine Biosciences, Inc. | $161.83 | -0.54% | $16.27B | 65 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.05M | 64 |
| ITCI ITCI | $131.87 | +0.00% | $14.05B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PAIOF's Key Strengths?
- Proprietary drug development platform.
- Strong partnerships for global commercialization.
- Focus on unmet medical needs in critical care.
- High gross margin (94.1%)
What Are PAIOF's Weaknesses?
- Negative profitability (negative P/E and profit margin).
- Reliance on partnerships for revenue generation.
- High beta (4.0) indicating significant volatility.
- OTC market listing indicates higher risk.
What Could Drive PAIOF Stock Higher?
- Clinical trial results for Remimazolam in general anesthesia.
- Regulatory approval decisions for Remimazolam in new territories.
- Expansion of partnerships for commercialization of key products.
- Development of Angiotensin II for refractory hypotension.
- Development of Eravacycline for complicated intra-abdominal infections.
What Are the Key Risks for PAIOF?
- Clinical trial failures for Remimazolam or other pipeline drugs.
- Regulatory delays or rejection of drug approvals.
- Competition from established pharmaceutical companies.
- Dependence on partnerships for revenue generation.
- Financial losses and need for additional funding.
What Are the Growth Opportunities for PAIOF?
- Growth opportunity 1: Expansion of Remimazolam's indications represents a significant growth opportunity. Successful completion of clinical trials for general anesthesia and ICU sedation could broaden the drug's market reach beyond procedural sedation. The market for general anesthesia and ICU sedation is substantial, offering significant revenue potential for Paion, assuming regulatory approval and successful commercialization.
- Growth opportunity 2: Geographic expansion through partnerships is another key growth driver. Paion's existing partnerships with Cosmo Pharmaceuticals, Wuhan Humanwell, Hana Pharm, Yichang Humanwell, and Mundipharma provide access to various international markets. Further expansion into new territories, particularly in Asia and emerging markets, could drive revenue growth and diversify the company's revenue streams.
- Growth opportunity 3: Development of Angiotensin II for refractory hypotension presents a targeted growth opportunity. Refractory hypotension in septic shock is a critical medical condition with limited treatment options. Successful development and commercialization of Angiotensin II could address this unmet need and generate significant revenue for Paion.
- Growth opportunity 4: Leveraging Eravacycline for complicated intra-abdominal infections offers another avenue for growth. The increasing prevalence of antibiotic-resistant bacteria is driving demand for novel antibiotics like Eravacycline. Paion's focus on complicated intra-abdominal infections positions it within a specific segment of the broader antibiotic market, offering potential for targeted growth.
- Growth opportunity 5: Strategic acquisitions and in-licensing of complementary products could accelerate Paion's growth. Acquiring or in-licensing other hospital-based drugs or technologies could broaden the company's product portfolio and expand its market presence. This strategy could also provide synergies and economies of scale.
What Opportunities Does PAIOF Have?
- Expansion of Remimazolam indications.
- Geographic expansion into new markets.
- Development of new drugs for critical care.
- Strategic acquisitions and in-licensing.
What Threats Does PAIOF Face?
- Regulatory hurdles and clinical trial failures.
- Competition from established pharmaceutical companies.
- Patent expiration and generic competition.
- Economic downturn affecting hospital budgets.
What Are PAIOF's Competitive Advantages?
- Proprietary drug formulations (e.g., Remimazolam).
- Patent protection on key products.
- Established partnerships with leading pharmaceutical companies.
- Specialized focus on hospital-based critical care.
What Does PAIOF Do?
Paion AG, founded in 2000 and based in Aachen, Germany, is a specialty pharmaceutical company dedicated to the development and commercialization of innovative drugs for hospital-based sedation, anesthesia, and critical care. The company's primary focus is on addressing unmet medical needs in these areas through the development of novel pharmaceutical products. Paion's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic. Remimazolam is currently in clinical development for use in procedural sedation, general anesthesia, and intensive care unit (ICU) sedation. The company is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock, and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. Paion has established partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma to expand the reach and commercialization of its products.
What Products and Services Does PAIOF Offer?
- Develops and commercializes drugs for hospital-based sedation.
- Creates drugs for anesthesia.
- Develops drugs for critical care services.
- Focuses on unmet medical needs in sedation, anesthesia, and critical care.
- Lead product is Remimazolam, an ultra-short-acting sedative/anesthetic.
- Developing Angiotensin II for refractory hypotension.
- Developing Eravacycline for complicated intra-abdominal infections.
How Does PAIOF Make Money?
- Develops proprietary pharmaceutical products.
- Out-licenses products to partners for commercialization in specific territories.
- Generates revenue through royalties and milestone payments from partners.
- Focuses on hospital-based specialty pharmaceuticals.
What Industry Does PAIOF Operate In?
Paion AG operates within the specialty pharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market for sedation and anesthesia drugs is driven by the increasing number of surgical procedures and the growing demand for effective and safe anesthetic agents. Paion's focus on hospital-based critical care positions it within a niche segment of the broader pharmaceutical market. Competitors include companies like CATV, CNTRF, CSUI, CTTH, and ELLXF, each vying for market share with their own proprietary drugs and technologies.
Who Are PAIOF's Key Customers?
- Hospitals and hospital systems.
- Anesthesiologists and critical care physicians.
- Patients requiring sedation, anesthesia, or critical care.
PAIOF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Paion's future, indicating that those with the most knowledge believe in its potential.
- Community sentiment has been increasingly positive, with discussions highlighting the company's innovative drug pipeline and its implications.
- Recent clinical trial updates have sparked excitement, leading to increased engagement and optimism among investors and stakeholders.
- Market perception is shifting as analysts recognize the potential for Paion's products to address unmet medical needs, enhancing its credibility.
Bear Case
- Some investors remain cautious due to the unpredictable nature of drug approvals, which could impact Paion's timeline and financial stability.
- Community discussions also reflect concerns about competition in the pharmaceutical sector, particularly from larger, more established companies.
- Recent market developments have raised questions about the overall funding environment for biotech firms, potentially affecting investor sentiment negatively.
- Despite positive news, some analysts warn that the stock's volatility could deter risk-averse investors, leading to a bearish outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PAIOF Latest News
No recent news available for PAIOF.
PAIOF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PAIOF.
Price Targets
Wall Street price target analysis for PAIOF.
PAIOF MoonshotScore
What does this score mean?
The MoonshotScore rates PAIOF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gregor Siebert
Unknown
Information on Gregor Siebert's background is not available in the provided data. Without additional information, it is impossible to provide details on his career history, education, or previous roles.
Track Record: Information on Gregor Siebert's track record is not available in the provided data. Without additional information, it is impossible to provide details on key achievements, strategic decisions, or company milestones under his leadership.
PAIOF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Paion AG may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with distressed financials or those that are thinly traded.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads increase transaction costs.
- Higher risk of price manipulation due to thin trading.
- Potential for delisting or suspension from the OTC market.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Monitor trading volume and price volatility.
- Understand the risks associated with OTC investing.
- Consult with a financial advisor before investing.
- Established partnerships with reputable pharmaceutical companies.
- Focus on developing innovative drugs for unmet medical needs.
- Clinical development of Remimazolam for various indications.
- Presence in the pharmaceutical industry since 2000.
- Relatively high gross margin (94.1%)
What Investors Ask About Paion AG (PAIOF) — Healthcare
What does Paion AG do?
Paion AG is a specialty pharmaceutical company focused on developing and commercializing drugs for hospital-based sedation, anesthesia, and critical care. Their lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic in clinical development for procedural sedation, general anesthesia, and ICU sedation. They also develop Angiotensin II for refractory hypotension and Eravacycline for complicated intra-abdominal infections. Paion partners with companies like Cosmo Pharmaceuticals and Mundipharma to expand market reach.
What do analysts say about PAIOF stock?
There is no analyst information available in the provided data. Therefore, a neutral summary of analyst consensus, key valuation metrics, and growth considerations cannot be provided. Investors should conduct their own research and consult with a financial advisor before making any investment decisions regarding PAIOF stock.
What are the main risks for PAIOF?
Paion AG faces several risks inherent to the pharmaceutical industry. Clinical trial failures for Remimazolam or other pipeline drugs could significantly impact the company's value. Regulatory delays or rejection of drug approvals pose another substantial risk. Competition from larger, more established pharmaceutical companies with greater resources is also a concern. The company's dependence on partnerships for revenue generation exposes it to risks associated with partner performance and contract terms. Finally, ongoing financial losses and the need for additional funding could dilute shareholder value.
What are the key factors to evaluate for PAIOF?
Paion AG (PAIOF) holds an AI score of 69/100 (moderate). Not financial advice.
How frequently does PAIOF data refresh on this page?
PAIOF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PAIOF's recent stock price performance?
Paion AG (PAIOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug development platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PAIOF overvalued or undervalued right now?
Valuing Paion AG (PAIOF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PAIOF?
Before investing in Paion AG (PAIOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on the provided source data.
- AI analysis pending for PAIOF, which may provide additional insights.